Research Topics
| D E CaseySummaryCountry: USA Publications
| Collaborators
|
Detail Information
Publications
Implications of the CATIE trial on treatment: extrapyramidal symptomsDaniel E Casey
Department of Psychiatry, Oregon Health and Science University, Portland, OR 97239, USA
CNS Spectr 11:25-31. 2006..This article explores the reported results of the CATIE trial regarding EPS and emphasizes the differentiation of the atypicals from perphenazine on EPS and how these results should be incorporated into daily practice for the clinician...- Atypical antipsychotics: enhancing healthy outcomesDaniel E Casey
Mental Illness Research, Education and Clinical Center, MIRECC VISN 20, Portland VA Medical Center and the Department of Psychiatry, Oregon Health Sciences University, Portland, OR 97201, USA
Arch Psychiatr Nurs 16:S12-9. 2002 - Metabolic issues and cardiovascular disease in patients with psychiatric disordersDaniel E Casey
UHN 80 Department of Psychiatry, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA
Am J Med 118:15S-22S. 2005..The costs associated with the treatment of the metabolic syndrome, diabetes, and coronary heart disease in populations with schizophrenia are also described... - Tardive dyskinesia and atypical antipsychotic drugsD E Casey
Mental Health Division, Veterans Affairs Medical Center, Portland, OR 97207, USA
Schizophr Res 35:S61-6. 1999..Because TD liability is so much lower with novel antipsychotic therapy, all patients who have TD or are at risk for TD, as well as EPS, should be considered candidates for switching to these new drugs... - Tardive dyskinesia: pathophysiology and animal modelsD E Casey
Mental Illness Research, Education and Clinical Center, Veterans Affairs Medical Center, Portland, OR 97201, USA
J Clin Psychiatry 61:5-9. 2000..Fortunately, the atypical antipsychotic agents appear to greatly decrease the liability of developing tardive dyskinesia, but how this occurs remains an open and fascinating line of inquiry... - Barriers to progress--the impact of tolerability problemsD E Casey
Psychiatric Research and Psychopharmacology, Mental Health Division, Veterans Affairs Medical Center, Portland, Oregon, USA
Int Clin Psychopharmacol 16:S15-9. 2001..The more favourable the benefit/risk ratios of these new drugs throughout all phases of treatment, the greater the likelihood that patients will have better outcomes... - Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized studyDaniel E Casey
Mental Health Division P3MIRECC, VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, OR 97239, USA
Psychopharmacology (Berl) 166:391-9. 2003..It is important to compare switching strategies to determine which methods produce the best possible patient outcomes... - Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophreniaDaniel E Casey
Mental Illness Research, Education, and Clinical Center, Portland VA Medical Center, OR 97201, USA
Neuropsychopharmacology 28:182-92. 2003..Further evaluation is warranted to confirm these findings... - The pharmacology of weight gain with antipsychoticsD E Casey
Portland Veterans Affairs Medical Center, Oregon Health Sciences University, USA
J Clin Psychiatry 62:4-10. 2001..In spite of this, an overview of current knowledge in the field may facilitate prediction of a potential novel antipsychotic agent's weight gain liability... - Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeysJ Gerlach
Dept of Psychiatry, Veterans Administration Medical Center, Portland, Oregon
Prog Neuropsychopharmacol Biol Psychiatry 14:103-12. 1990.... - The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primatesD E Casey
Mental Health Division (P-3-MHDC, VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, OR 97207, USA
Psychopharmacology (Berl) 157:228-35. 2001.... - Clinical trial design issues in schizophrenic researchD E Casey
Mental Illness Research, Education and Clinical Center, Veterans Administration Medical Center, and the Oregon Health Sciences University, Portland 97201, USA
J Clin Psychiatry 62:17-20; discussion 21-2. 2001..This article discusses the 2 major goals of research studies, the design issues associated with those goals, and the design features of several recent comparative studies of atypical antipsychotics... - Dyslipidemia and atypical antipsychotic drugsDaniel E Casey
Department of Psychiatry, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
J Clin Psychiatry 65:27-35. 2004.... - Metabolic effects of treatment with atypical antipsychoticsJohn M Kane
Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA
J Clin Psychiatry 65:1447-55. 2004 - Physical health monitoring of patients with schizophreniaStephen R Marder
Department of Veterans Affairs Greater Los Angeles Healthcare System, CA, USA
Am J Psychiatry 161:1334-49. 2004..The authors discuss a consensus panel's recommendations for improving the physical health monitoring of patients with schizophrenia who are treated in outpatient settings... - Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophreniaDaniel E Casey
J Clin Psychiatry 65:4-18; quiz 19-20. 2004 - Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidoneLeslie Citrome
Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
Psychiatr Serv 55:290-4. 2004.... - Long-term treatment goals: enhancing healthy outcomesDaniel E Casey
Oregon Health and Science University, Portland, Oregon, USA
CNS Spectr 8:26-8. 2003..These drugs are likely to provide physicians with an increasingly viable option in the long-term treatment and rehabilitation of patients with schizophrenia... - Effect of a novel potential atypical antipsychotic drug, Y-931, in producing dystonia in cebus monkeysYasuyuki Shiigi
Research Laboratory I CNS, Pharmaceuticals Research Unit, Research and Development Division, Mitsubishi Pharma Corporation, Iruma, Saitama, Japan
J Pharmacol Sci 93:364-6. 2003..5 mg/kg, i.m., the scores did not exceed 20, up to a dose of 1.0 mg/kg, i.m. and lacked a dose-response relationship. The present result suggests that Y-931 is predicted to have a low risk of extrapyramidal side effects... - Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placeboGilbert J L'italien
Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
J Clin Psychiatry 68:1510-6. 2007.... - Pathophysiology of antipsychotic drug-induced movement disordersDaniel E Casey
Department of Psychiatry and Neurology, Oregon Health and Sciences University, Portland, OR 97321, USA
J Clin Psychiatry 65:25-8. 2004..A number of factors contribute to the difficult task of gaining insight into the pathophysiologic processes of antipsychotic agents and why these agents may lead to drug-induced movement disorders... - Schizophrenia and increased risks of cardiovascular diseaseCharles H Hennekens
Department of Biomedical Science, Center of Excellence in Biomedical and Marine Biotechnology, Florida Atlantic University, FL, USA
Am Heart J 150:1115-21. 2005..The aim of the study is to review the absolute and relative impacts of the major causes for premature mortality among patients with schizophrenia... - Response to letter to the editor by Dr MackinCharles H Hennekens
Am Heart J 152:e59. 2006